May 29 Webinar- Meet HiveBio’s Inaugural Cohort
- Caroline Okun
- May 12
- 1 min read
Join LaunchBio as they introduce the HiveBio inaugural cohort. During this live virtual event, they will introduce the 10 exceptional startups selected for HiveBio’s inaugural cohort. The cohort includes the following 10 companies:
Ajaya Bio: Developing BOLT-360™, a bispecific platform enhancing specificity, safety, and access to previously untargetable pathways in autoimmune diseases and oncology.
BioLattice Ophthalmics: Innovating biomimetic, cell-friendly scaffolds to enhance ophthalmic tissue replacement and advance corneal treatment.
Bound Therapeutics: Creating novel cancer therapies with a robust preclinical program to support future drug development for triple-negative breast cancer.
Cerespectus: Medical device start-up pioneering gene therapeutic pathways to support neurological health.
DRS.LINQ: Medical device start-up redefining remote monitoring for cardiovascular disease with mHeart, which enables mobile triage, real-time monitoring, and rapid heart disease diagnostics during episodes of patient chest discomfort.
Higher Medicine: Rare disease start-up ushering in a new age of functional cures for Friedreich’s ataxia (FA) patients.
QuneUp: Biotech software start-up digitizing “preventive actions”, in-line validation & other quality control operations for laboratory and biomanufacturing equipment.
Trevarx Biomedical: Drug therapeutic start-up utilizing PARP inhibitor (PARPi) analogues with radiopharmaceutical platforms to support treatments in oncology.
Valfard Therapeutics: Pioneering innovative biomaterial-based growth factor delivery for treating Stage I & II diabetic foot ulcers.
Vasowatch: Pioneering novel technology to provide continuous monitoring of a mother’s risk for postpartum hemorrhage and excessive blood loss after childbirth - the leading causes of maternal deaths globally.
